XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
I
I

IQVIA

News

Reuters - 1 week ago

India's Aurobindo Pharma up on FDA nod for product treating menopause condition

BUZZ-India's Aurobindo Pharma up on FDA nod for product treating menopause condition ** Shares of Aurobindo Pharma ARBN.NS rise as much as 2.7% to 1,439.90 rupees, among top gainers in Nifty Pharma index .NIPHARM ** Co on Tuesday received U.S. FDA nod to make and market estradiol vaginal suppositories - a bioequivalent to Novo Nordisk's VAGIFEM - used treat a condition resulting from menopause ** Product has estimated market size of $268 million for the 12 months ended June 2024, as per pharma c
I
Reuters - 3 weeks ago

Medpace tumbles after bookings disappoint

BUZZ-Medpace tumbles after bookings disappoint ** Medpace's MEDP.O shares down 13.6% premarket to three-mth low $377.91 after clinical contract research organization's bookings miss expectations ** Co late Mon reported Q2 new business awards decreased 4% yr/yr for net book-to-bill ratio (number of orders received to those fulfilled) of 1.04x ** TD Cowen, which rates MEDP "buy", pointed out that consensus called for book-to-bill ratio of 1.23x ** While unclear what drove bookings weakness, some e
I
Reuters - 3 weeks ago

U.S. Colgate-Palmolive, McKesson, Microsoft

U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft July 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Colgate-Palmolive, McKesson and Microsoft, on Tuesday. HIGHLIGHTS * Colgate-Palmolive Co CL.N : TD Cowen initiates coverage with buy rating; PT $110 * DR Horton Inc DHI.N : JP Morgan raises target price to $180 from $163 * IQVIA Holdings Inc IQV.N : Baird raises target price to $251 from $235 * McKesso
C
H
M
M
T
V
Z
F
A
M
A
C
C
D
I
Reuters - 3 weeks ago

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change IQVIA Holdings Inc IQV.N +7.7% Lam Research Corp LRCX.OQ +6% ON Semiconductor Corp ON.OQ +5.9% Applied Materials Inc AMAT.OQ +5.8% KLA Corp KLAC.OQ +5.5% Bottom Performers Percent Change CrowdStrike Holdings Inc CRWD.OQ -13.2% Verizon
S
V
K
L
O
U
A
C
I
Reuters - 3 weeks ago

U.S. STOCKS Walt Disney, Mattel, Tellurian

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, Mattel, Tellurian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq recouped some of the previous week's losses on Monday, as investors reexamined the chances of a second presidential term for Republican nominee Donald Trump after U.S.
G
M
N
S
S
V
A
C
L
U
U
A
G
I
N
Reuters - 3 weeks ago

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change IQVIA Holdings Inc IQV.N +6.6% ON Semiconductor Corp ON.OQ +4.7% Lam Research Corp LRCX.OQ +4.2% Applied Materials Inc AMAT.OQ +3.9% KLA Corp KLAC.OQ +3.9% Bottom Performers Percent Change CrowdStrike Holdings Inc CRWD.OQ -13.0% Verizo
S
V
K
L
O
U
A
C
I
Reuters - 3 weeks ago

U.S. STOCKS Verizon Communications, Reddit, Starbucks

BUZZ-U.S. STOCKS ON THE MOVE-Verizon Communications, Reddit, Starbucks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street rose on Monday, regaining some ground after the previous week's declines as investors assessed the odds of a second term for Republican nominee Donald Trump in the November election after President Joe Biden withdrew from the race.
G
N
S
S
V
A
C
L
O
U
U
G
I
Reuters - 3 weeks ago

IQVIA climbs on annual profit forecast raise

BUZZ-IQVIA climbs on annual profit forecast raise ** Shares of contract research firm IQVIA Holdings IQV.N rise ~6.7% to $239.60, highest since April ** Co forecasts annual adj. profit between $11.10 and $11.30 per share, above its prior range of $10.95 to $11.25 ** Co reports Q2 adj. profit of $2.64/shr vs analysts' average estimate of $2.57/shr -
I
Reuters - 3 weeks ago

IQVIA Holdings Inc reports results for the quarter ended in January - Earnings Summary

IQVIA Holdings Inc reports results for the quarter ended in January - Earnings Summary IQVIA Holdings Inc IQV.N reported quarterly adjusted earnings of $2.64​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $2.43. The mean expectation of twenty one analysts for the quarter was for earnings of $2.57 per share.
I
Reuters - 3 weeks ago

IQVIA raises annual profit forecast on improving demand for analytics services

IQVIA raises annual profit forecast on improving demand for analytics services July 22 (Reuters) - Contract research firm IQVIA Holdings IQV.N raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services. Technological and analytical solutions (TAS), IQVIA's second-largest unit, reported a 2.7% rise in second-quarter revenue to $1.50 billion, above estimates of $1.47 billion, according to LSEG data.
I
Reuters - 3 weeks ago

IQVIA Q2 Adjusted EPS USD 2.64 Vs. IBES Estimate USD 2.57

BRIEF-IQVIA Q2 Adjusted EPS USD 2.64 Vs. IBES Estimate USD 2.57 Jul 22 (Reuters) - IQVIA Q2 net income USD 363 million. Q2 revenue USD 3,814 million vs. IBES estimate USD 3,789 million Q2 adjusted EBITDA USD 887 million vs. IBES estimate USD 884 million Q2 EPS USD 1.97
I
Reuters - 3 weeks ago

Biden bows out, election bets shift, China cuts

MORNING BID AMERICAS-Biden bows out, election bets shift, China cuts A look at the day ahead in U.S. and global markets from Mike Dolan U.S. President Joe Biden's weekend withdrawal from the White House race can hardly be seen as a big surprise, but it adds some doubts to market bets that Republican challenger Donald Trump is a shoo-in in November's election.
B
C
D
G
G
L
N
N
T
U
U
V
G
J
U
U
U
F
W
I
Reuters - 4 weeks ago

IQVIA Holdings Inc <IQV.N> expected to post earnings of $2.57 a share - Earnings Preview

IQVIA Holdings Inc expected to post earnings of $2.57 a share - Earnings Preview IQVIA Holdings Inc IQV.N , IQV is expected to show a rise in quarterly revenue when it reports results on July 22 for the period ending June 30 2024 The Durham North Carolina-based company is expected to report a 1.6% increase in revenue to $3.789 billion from $3.73 billion a year ago, according to the mean estimate from 18 analysts, based on LSEG data.The company's guidance on May 2 2024, for the period ended June
I
Reuters - 4 weeks ago

Novo Nordisk obesity feast no longer a free lunch

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO is going to have to work hard to justify its bulging valuation. The $603 billion obesity drug maker’s shares have more than trebled since 2021 thanks to insatiable appetite for its weight-loss drug.
A
P
R
I
Reuters - 2 months ago

U.S. Avidity Biosciences, Broadcom, Cara Therapeutics

U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday. HIGHLIGHTS * Avidity Biosciences Inc RNA.O : Leerink Partners raises target price to $56 from $38 * Broadcom Inc AVGO.O : TD Cowen raises target price to $1,750 from $1,500 * Cara Therapeutics Inc CARA.O : Canaccord Genuity cut
B
B
C
C
G
M
C
A
D
I
L
Reuters - 2 months ago

Iqvia Launches “One Home” Clinical Trial Technology Platform – Solves Challenges And Reduces Overload At Sites

BRIEF-Iqvia Launches “One Home” Clinical Trial Technology Platform – Solves Challenges And Reduces Overload At Sites June 12 (Reuters) - IQVIA Holdings Inc IQV.N : IQVIA LAUNCHES “ONE HOME” CLINICAL TRIAL TECHNOLOGY PLATFORM – SOLVES CHALLENGES AND REDUCES OVERLOAD AT SITES Source text for Eikon: ID:nBw7w4l7Ta Further company coverage:
I
Reuters - 2 months ago

UK's Hikma gains as Citi raises target price

BUZZ-UK's Hikma gains as Citi raises target price ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 3% at 1,989p ** Stock is top pct gainer on FTSE 100 index .FTSE ** Brokerage Citigroup raises target price to 2845p from 2770p ** Research firm IQVIA's data on HIK highly encouraging; we go to the top-end of forecast range - Citi ** Hikma
H
U
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.